Alzheimer Dementia
56
9
11
21
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.4%
3 terminated out of 56 trials
87.5%
+1.0% vs benchmark
7%
4 trials in Phase 3/4
33%
7 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (56)
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease
Fisetin in Mild Alzheimer's Disease
Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Innate Immunity Stimulation Via TLR9 in Early AD
Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research
Environmental Pollutants and Neurological Disorders
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Statins, Cholesterol and Cognitive Decline in Alzheimer's
Medication Repurposing to Stop Cognitive Decline in Dementia
Treating Hyperexcitability in AD With Levetiracetam
Effects of Visual Cues and Education for People Who Live Within Long Term Care Communities to Assist in Wayfinding
Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease
The Senior Companion Program Plus